HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper

    Thumbnail
    Download
    Citations
    Web of Science
    Altmetric
    1
    Author
    Fidler, S; Lewin, S; Deeks, S; Sogaard, OS; Vandekerckhove, L; Collins, S; Kelly, D; Singh, J; Caskey, M; Frater, J
    Date
    2021-03-01
    Source Title
    Journal of virus eradication
    Publisher
    MEDISCRIPT LTD
    University of Melbourne Author/s
    Lewin, Sharon
    Affiliation
    Doherty Institute
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Fidler, S., Lewin, S., Deeks, S., Sogaard, O. S., Vandekerckhove, L., Collins, S., Kelly, D., Singh, J., Caskey, M. & Frater, J. (2021). HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper. JOURNAL OF VIRUS ERADICATION, 7 (1), https://doi.org/10.1016/j.jve.2020.100025.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/272396
    DOI
    10.1016/j.jve.2020.100025
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719279
    Abstract
    This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.

    Export Reference in RIS Format     

    Publisher licence
    CC BY-NC-ND
    Collections